Print

BRIDGEWATER, NJ – March 19, 2009 – Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new novel Locked Nucleic Acid (LNA) programs directed against, the Androgen receptor (AR) and Phosphoinositide 3-kinase (PI3K/Akt)."  These targets are linked to a broad spectrum of cancers."  Enzon has licensed eight novel LNA targets from Santaris Pharma A/S.

The abstracts related to these new targets and other Enzon programs are now available at" www.aacr.org."  These data will be presented at the upcoming 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2009 in Colorado.

"Novel releasable PEG-nanoparticles enhance delivery of RNA antagonist oligonucleotides in tumor cells and in mice"(Abstract #646)
Poster Presentation from 8:00 am to 12:00 pm local time on Sunday, April 19, 2009.

"EZN-2208, a novel pegylated SN-38 drug conjugate, markedly inhibits tumor growth and metastatic spreading of human neuroblastoma" (Abstract #1699)
Poster Presentation from 1:00 to 5:00 pm local time on Sunday, April 19, 2009.

"Androgen receptor (AR) down regulation by locked nucleic acid antisense oligonucleotides specifically inhibits the growth of AR-positive tumor cells" (Abstract #4631)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

"The antitumor activity of EZN-4150, a potent LNA-based PIK3CA antagonist" (Abstract #4634)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

"EZN-3042, a novel locked nucleic acid oligonucleotide against survivin, inhibits survivin expression and confers taxol sensitivity" (Abstract #4633)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

"EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K/Akt signaling pathway and enhances antiproliferative effect of Gefitinib in tumor cells" (Abstract #4630)
Poster Presentation from 1:00 to 5:00 pm local time on Tuesday, April 21, 2009.

About Enzon" 
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar"®, DepoCyt"®, Abelcet"® and Adagen"®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at" www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon’s products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the period ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman
EVP, Finance and Chief Financial Officer
908-541-8777